Equity Issuances

INSPIRE VETERINARY PARTNERS, INC. issued up to 2,500,000 shares of common stock of common stock to Manetto Hill Fund Series I LLC.

“Pursuant to the securities purchase agreement, in connection with the issuance of the Note, the Company agreed to issue up to 2,500,000 shares of common stock to Manetto (the “Commitment Shares”).”

INSPIRE VETERINARY PARTNERS, INC. issued convertible note to Manetto Hill Fund Series I LLC for $975,000 principal amount for a purchase price of $750,000.

“On January 6, 2026, effective as of December 31, 2025, the Company issued to a secured convertible promissory note in the principal amount of $975,000 for a purchase price of $750,000 (the “Note”).”

BRAINSTORM CELL THERAPEUTICS INC. issued shares of common stock issuable upon conversion of the Notes of convertible note to accredited investors for not specified.

“The Notes, and the shares of the Company’s common stock issuable upon conversion of the Notes, if any, were or will be issued in reliance upon the exemption from registration provided by Section 4(a)(2) of the Securities Act and/or Rule 506 of Regulation D thereunder.”

XTI Aerospace, Inc. issued pre-funded warrant to purchase 15,307,735 shares of Common Stock of warrant to Unusual Machines, Inc. for issued in lieu of Common Stock due to beneficial ownership limitation; exercise price of $0.0001 per share deemed pre-paid as part of the Subscription Amount.

“Stock. The Pre-Funded Warrant is immediately exercisable and may be exercised at any time until it is exercised in full. The Pre-Funded Warrant has an exercise price of $0.0001 per share, provided that such exercise price is deemed pre-paid as part of the Subscription Amount. The Pre-Funded Warrant may not be exercised if the holder thereof (together”

XTI Aerospace, Inc. issued 1,721,980 shares of Common Stock of common stock to Unusual Machines, Inc. for conversion of $25,000,000 Series 10 Convertible Preferred Stock plus accrued dividends.

“As a result of the automatic conversion of the Series 10 Preferred Stock, on January 5, 2026, the Company issued Unusual Machines 1,721,980 shares of Common Stock (the “Shares”) and a pre-funded warrant to purchase 15,307,735 shares of Common Stock (the “Pre-Funded Warrant” and the shares of Common Stock issuable upon exercise of the Pre-Funded Warrant, the “Pre-Funded Warrant Shares”).”

City Office REIT, Inc. issued preferred stock for Preferred Merger Consideration.

“each share of Series A Preferred Stock that was issued and outstanding prior to the Effective Time was redeemed, prior to the Effective Time, in exchange for the Preferred Merger Consideration”

City Office REIT, Inc. issued common stock for $7.00 per share.

““MCME Carell”) announced today that MCME Carrell has completed its previously announced acquisition of City Office REIT, Inc. (NYSE: CIO) (“City Office REIT” or “CIO”) for $7.00 per share of common stock. As a result of the transaction, CIO’s common stock will no longer be listed on any public market. James Farrar, City Office REIT’s Chief Executive”

Aptevo Therapeutics Inc. issued common stock to YA II PN, LTD. for up to $60.0 million.

“to the Purchase Agreement, the Company has the right, but not the obligation, to issue and sell to Yorkville from time to time (each such occurrence, an “Advance”) up to $60.0 million (the “Commitment Amount”) of the Company’s common stock, $0.001 par value per share (“Common Stock”), during the 36 months following the execution of the Purchase Agreement,”

Momentus Inc. issued 925,926 shares of the Company’s Class A common stock of warrant to an investor for aggregate gross proceeds from the Private Placement of approximately $5 million.

“collectively, the “Securities”). The Private Placement closed on January 6, 2026. The Company received aggregate gross proceeds from the Private Placement of approximately $5 million, before deducting estimated placement agent commissions and expenses in connection with the Private Placement, which are payable by the Company. The Securities Purchase”

Evolution Metals & Technologies Corp. issued common stock.

“On the Closing Date, in connection with the consummation of the Business Combination, the Company adopted the Amended and Restated Certificate of Incorporation of EMAT (as amended and restated, the “Charter”) and the Amended and Restated Bylaws of EMAT (as amended and restated, the “Bylaws”). The Charter became effective upon filing with the Secretary of State of the State of Delaware on January 5, 2026 and includes the amendments proposed by the Advisory Governance Proposals.”

ConnectM Technology Solutions, Inc. issued 15,000,000 shares of common stock of common stock to Caleb Arthur or his assignees.

“On January 5, 2026, the Company issued 15,000,000 shares of common stock of the Company to Mr. Arthur or his assignees in connection with the Acquisition Agreement.”

High Roller Technologies, Inc. issued 357,143 shares of common stock to an accredited investor for $2.80 per share.

“On January 8, 2026, High Roller Technologies, Inc. (the “Company”) entered into a stock purchase agreement (the “Purchase Agreement”) with an accredited investor (the “Investor”), pursuant to which the Company agreed to issue and sell to the Investor in a private placement (the “Private Placement”) an aggregate of 357,143 shares (the “Shares”) of the Company’s common stock, par value $0.001 per share, at a purchase price of $2.80 per share.”

Macquarie Infrastructure Fund, L.P. issued 110.00 of unit to accredited investors and qualified purchasers for approximately $2,750.

“On December 1, 2025, Macquarie Infrastructure Fund, L.P. (the “Fund”) sold unregistered limited partnership units (the “Units”) for aggregate consideration of approximately $2,750 .”

Soren Acquisition Corp. issued 1,100,000 Class A Ordinary Shares of common stock to BTIG, LLC for issued upon the consummation of the Offering, as part of the underwriting arrangement.

“The Company also issued in a private placement to BTIG 1,100,000 Class A Ordinary Shares upon the consummation of the Offering (the “Representative Shares”).”

Soren Acquisition Corp. issued 5,000,000 warrants of warrant to Soren Holdings LLC for at a purchase price of $1.00 per Private Placement Warrant, generating gross proceeds to the Company of $5,000,000.

“Simultaneously with the closing of the Offering, pursuant to the Private Placement Warrants Purchase Agreement, the Company completed the private sale of an aggregate of 5,000,000 warrants (the “ Private Placement Warrants ”) to the Sponsor at a purchase price of $1.00 per Private Placement Warrant, generating gross proceeds to the Company of $5,000,000.”

Black Spade Acquisition III Co issued 1,150,000 Private Placement Warrants of warrant to the Underwriters for $0.50 per Private Placement Warrant.

“the sale of 1,150,000 Private Placement Warrants to the Underwriters at a purchase price of $0.50 per Private Placement Warrant, generating gross proceeds to the Company of $575,000”

Black Spade Acquisition III Co issued 7,000,000 Private Placement Warrants of warrant to Black Spade Sponsor LLC III (the Sponsor) for $0.50 per Private Placement Warrant.

“the Company completed the private sales of 8,150,000 warrants (the “ Private Placement Warrants ”), including the sale of 7,000,000 Private Placement Warrants to Black Spade Sponsor LLC III (the “ Sponsor ”) at a purchase price of $0.50 per Private Placement Warrant, generating gross proceeds to the Company of $3,500,000”

Bleichroeder Acquisition Corp. II issued 7,750,000 warrants of warrant to Sponsor and Cohen & Company Capital Markets, as Lead Book-Running Manager and representative of the underwriters, and Clear Street LLC, as Co-Manager for $1.00 per Private Placement Warrant.

“Simultaneously with the closing of the IPO, pursuant to the Sponsor Private Placement Warrants Purchase Agreement and the Underwriter Private Placement Warrants Purchase Agreement, the Company completed the private sale of an aggregate of 7,750,000 warrants (the “ Private Placement Warrants ”) to the Sponsor and Cohen & Company Capital Markets, as Lead Book-Running Manager and representative of the underwriters, and Clear Street LLC, as Co-Manager, at a price of $1.00 per Private Placement Warrant.”

CAMPBELL FUND TRUST issued unit to existing and/or new unitholders for aggregate $2,378,900.00, $2,917,413.71 and $1,502,000.00 in cash for Series A, Series D and Series W, respectively.

“Act of 1933, as amended (the “Securities Act”). The aggregate estimate consideration for Units of Beneficial Interest, excluding escrow interest, sold on December 31, 2025 was $2,378,900.00, $2,917,413.71 and $1,502,000.00 in cash for Series A, Series D and Series W, respectively. The Units of Beneficial Interest were issued by Registrant in reliance upon an”

Alaunos Therapeutics, Inc. issued common stock.

“On January 8, 2026, the Board of Directors of the Company approved and adopted Amended and Restated By-Laws of the Company (the “Amended and Restated Bylaws”), effective immediately.”

CURIS INC issued 26,926,675 shares of Common Stock of warrant to the purchasers named therein for purchase price of $1,000.00 per Security.

“shares of Common Stock and a Series C Warrant to purchase 1,333.33 shares of Common Stock (collectively, a “Security”). The Securities will be sold at a purchase price of $1,000.00 per Security to the Purchasers, which includes the Company’s Chief Executive Officer, Chief Financial Officer, Chief Medical Officer, Chief Development Officer and a member of the”

CURIS INC issued 26,926,675 shares of the Company’s common stock of warrant to the purchasers named therein for purchase price of $1,000.00 per Security.

“shares of Common Stock and a Series C Warrant to purchase 1,333.33 shares of Common Stock (collectively, a “Security”). The Securities will be sold at a purchase price of $1,000.00 per Security to the Purchasers, which includes the Company’s Chief Executive Officer, Chief Financial Officer, Chief Medical Officer, Chief Development Officer and a member of the”

CURIS INC issued 20,195 shares of its Series B convertible non-redeemable preferred stock of preferred stock to the purchasers named therein for purchase price of $1,000.00 per Security.

“shares of Common Stock and a Series C Warrant to purchase 1,333.33 shares of Common Stock (collectively, a “Security”). The Securities will be sold at a purchase price of $1,000.00 per Security to the Purchasers, which includes the Company’s Chief Executive Officer, Chief Financial Officer, Chief Medical Officer, Chief Development Officer and a member of the”

Ares Real Estate Income Trust Inc. issued 1,570,046 of common stock to accredited investors for $12,551,891.

“table details the shares issued and gross proceeds : Number of Shares Issued Gross Proceeds Class S-PR Shares (1)(2) 681,448 $ 5,495,957 Class I-PR Shares (1) 1,570,046 $ 12,551,891 _________________________ (1) Number of shares issued and gross proceeds include activity from shares issued pursuant to our distribution reinvestment plan. (2) Gross proceeds for”

Ares Real Estate Income Trust Inc. issued 681,448 of common stock to accredited investors for $5,495,957.

“as amended, pursuant to Regulation D. The following table details the shares issued and gross proceeds : Number of Shares Issued Gross Proceeds Class S-PR Shares (1)(2) 681,448 $ 5,495,957 Class I-PR Shares (1) 1,570,046 $ 12,551,891 _________________________ (1) Number of shares issued and gross proceeds include activity from shares issued pursuant to our”

RYVYL Inc. issued 122,164 shares of common stock to settlement class represented by lead plaintiff Scot S. Cook for settlement with the plaintiffs in the Class Action in reliance on the exemption from registration under Section 3(a)(10).

“of July 9, 2025, between RYVYL Inc. (the “Company”) and the other parties named therein (the “Settlement Agreement”) in connection with the putative class action lawsuit Case No. 3:23-cv-00185-GPC-SBC (the “Class Action”), on January 2, 2026, the Company became obligated to issue 122,164 shares (the “Settlement Shares”) of its common stock, par value $0.001”

Blackstone Real Estate Income Trust, Inc. issued 874,792 of common stock to accredited investors for aggregate consideration of approximately $12.3 million.

“On January 2, 2026, Blackstone Real Estate Income Trust, Inc. (the “Company”) sold unregistered shares of the Company’s common stock (the “Shares”) for aggregate consideration of approximately $12.3 million.”

SPRUCE BIOSCIENCES, INC. issued common stock to Avenue Capital Management II, L.P. (as Agent) for up to $4.0 million of the outstanding principal.

“the Lender will have the right to convert up to $4.0 million of the outstanding principal of the Loans (the “Conversion Option”) at a price per share equal to 120% of the exercise price of the Warrant”

SPRUCE BIOSCIENCES, INC. issued warrant to Avenue Venture Opportunities Fund II, L.P. for up to $3,200,000 worth of shares.

“the Company will issue to the Lender a warrant (the “Warrant”) to purchase up to $3,200,000 worth of shares of the Company’s common stock”

Cottonwood Communities, Inc. issued 115,212 shares of Series 2025 Preferred Stock of preferred stock to accredited investors for aggregate proceeds of $1,095,000.

“During the period from December 15, 2025 through January 7, 2026, we issued and sold 115,212 shares of Series 2025 Preferred Stock in the Series 2025 Private Offering and received aggregate proceeds of $1,095,000.”

Canopy Growth Corp issued 9,493,670 Common Shares of common stock to MMCAP International Inc. SPC for Issued as partial consideration under Exchange Agreement for delivery of C$96,358,375 principal amount of old convertible debentures.

“the Investor delivered to the Company C$96,358,375 aggregate principal amount of senior unsecured convertible debentures of the Company maturing in May 2029 held by the Investor in exchange for (A) the Company issuing to the Investor (i) new senior unsecured convertible debentures of the Company with an aggregate principal amount of C$55,000,000 maturing on July 8, 2031 (the “ Convertible Debentures ”), (ii) 12,731,481 common share purchase warrants (the “ Investor Warrants ” and together with the Loan Warrants, the “ Warrants ”) of the Company, and (iii) 9,493,670 Common Shares (the “ Exchange Shares ”)”

Canopy Growth Corp issued 12,731,481 common share purchase warrants of warrant to MMCAP International Inc. SPC for Issued in exchange for C$96,358,375 aggregate principal amount of senior unsecured convertible debentures.

“the Investor delivered to the Company C$96,358,375 aggregate principal amount of senior unsecured convertible debentures of the Company maturing in May 2029 held by the Investor in exchange for (A) the Company issuing to the Investor (i) new senior unsecured convertible debentures of the Company with an aggregate principal amount of C$55,000,000 maturing on July 8, 2031 (the “ Convertible Debentures ”), (ii) 12,731,481 common share purchase warrants (the “ Investor Warrants ””

Canopy Growth Corp issued 18,705,577 common share purchase warrants of warrant to Lenders for Issued in connection with Loan Agreement; lenders advanced US$150,000,000 under a senior secured loan.

“as lenders (the “ Lenders ”), and JGB Collateral LLC, as administrative and collateral agent (the “ Agent ”), pursuant to which, among other things, the Lenders advanced US$150,000,000 pursuant to a senior secured loan in the aggregate principal amount of US$162,115,000 (collectively, the “ Loans ” and such transaction, the “ Loan Transaction ”). The Loans were”

Beneficient issued 302,273 shares of the Company's Series B-9 Resettable Convertible Preferred Stock of preferred stock to a customer for limited partner interest in an investment fund with a net asset value of $3,022,728.

“On January 5, 2026, Beneficient, a Nevada corporation (the “Company”), through one of its subsidiaries, funded the closing of a primary capital transaction pursuant to definitive agreements entered into on December 31, 2025 with a customer with respect to a limited partner interest in an investment fund with a net asset value of $3,022,728 (the “Transaction”). Pursuant to the Transaction, the Company’s customized trust vehicles acquired a limited partner interest, and in exchange for such, the customer received 302,273 shares of the Company’s Series B-9 Resettable Convertible Preferred Stock, par value $0.001 per share (the “Series B-9 Preferred Stock”), with such Series B-9 Preferred Stock being convertible into shares of the Company’s Class A Common Stock, par value $0.001 per share (the “Class A Common Stock”).”

Century Therapeutics, Inc. issued 92,030,595 shares of common stock of common stock to institutional accredited investors for $1.15 per share and accompanying Common Warrant to purchase 0.5 shares of Common Stock.

“On January 7, 2026, Century Therapeutics, Inc. (the “Company”), entered into a securities purchase agreement (the “Purchase Agreement”) with certain institutional accredited investors (the “Investors”), pursuant to which the Company agreed to issue and sell to the Investors in a private placement (a) (i) 92,030,595 shares (the “Shares”) of common stock, par value $0.0001 per share (“Common Stock”), of the Company, and/or, (ii) pre-funded warrants to purchase 25,360,704 shares of Common Stock (“Pre-Funded Warrants”) and (b) warrants to purchase 58,695,648 shares of Common Stock or Pre-Funded Warrants in lieu thereof (“Common Warrants”, together with the Pre-Funded Warrants, the “Warrants”) at a purchase price of $1.15 per share and accompanying Common Warrant to purchase 0.5 shares of Common Stock or Pre-Funded Warrant and a purchase price of $1.1499 per Pre-Funded Warrant and accompanying Common Warrant to purchase 0.5 shares of Common Stock or Pre-Funded Warrant (the “Private Placemen”

EQT Exeter Real Estate Income Trust, Inc. issued 220.616 shares of Class E common stock of common stock to two of the Company's independent directors for $11.44 per share.

“On December 10, 2025, EQT Exeter Real Estate Income Trust, Inc. (the “Company”) issued 220.616 shares of Class E common stock at a price per share of $11.44 to two of the Company’s independent directors, for an aggregate purchase price of approximately $2.52 thousand.”

WEBTOON Entertainment Inc. issued 2,666,757 shares of common stock to a wholly owned indirect subsidiary of The Walt Disney Company ("Disney") for aggregate purchase price of $32,774,443.53.

“On January 8, 2026, WEBTOON Entertainment Inc. (the “Company”) entered into a Securities Purchase Agreement (the “Purchase Agreement”) with a wholly owned indirect subsidiary of The Walt Disney Company (“Disney”), pursuant to which Disney purchased 2,666,757 shares of the Company’s common stock, par value $0.0001 per share (the “Shares”), representing an approximately 2% equity interest in the Company, for an aggregate purchase price of $32,774,443.53.”

Principal Credit Real Estate Income Trust issued 106,460.06 common shares of common stock to third party investors and one or more officers and trustees of the Company for aggregate consideration of approximately $2,183,000.00.

“on January 2, 2026, the Company sold an aggregate of 106,460.06 common shares (the “Shares”) for aggregate consideration of approximately $2,183,000.00, to third party investors and one or more officers and trustees of the Company”

Goldman Sachs Real Estate Finance Trust Inc issued 111,630.698 shares of common stock to accredited investors for $2,793,000 aggregate.

“table details the Shares sold: Title of Securities* Number of Shares Sold Aggregate Consideration Class I Common Stock 449,361.528 $ 11,261,000 Class S Common Stock 111,630.698 $ 2,793,000 (1) (1) Includes upfront selling commissions of $33,560. * The Company views the different series of common stock (Series T, Series S, Series D and Series I) as being part of the”

Goldman Sachs Real Estate Finance Trust Inc issued 449,361.528 shares of common stock to accredited investors for $11,261,000 aggregate.

“and Regulation D thereunder. The following table details the Shares sold: Title of Securities* Number of Shares Sold Aggregate Consideration Class I Common Stock 449,361.528 $ 11,261,000 Class S Common Stock 111,630.698 $ 2,793,000 (1) (1) Includes upfront selling commissions of $33,560. * The Company views the different series of common stock (Series T, Series S,”

Wellgistics Health, Inc. issued up to $3,125,000 in aggregate principal amount of convertible promissory notes of convertible note to certain investors for aggregate purchase price of $2,500,000, reflecting a 20% original issue discount.

“amount (the “Aggregate Principal Amount”) of convertible promissory notes (the “Notes”) (the “Offering”). The aggregate purchase price payable by all Investors for the Notes is $2,500,000, reflecting a 20% original issue discount. All principal and interest on the outstanding principal will accrue and, unless converted earlier as set forth below, be due and”

Ares Core Infrastructure Fund issued common stock for aggregate purchase price of $284.6 million.

“In its monthly closing for January 2026, Ares Core Infrastructure Fund (the “Fund”) has agreed to sell common shares of beneficial interest ("Common Shares"), including Class I Common Shares (“Class I Shares”) and Class S Common Shares (“Class S Shares”) for an aggregate purchase price of $284.6 million.”

Art Technology Acquisition Corp. issued 825,000 Units of unit to Clear Street (295,000 Units) and Art Technology Sponsor, LLC (530,000 Units) for $10.00 per Placement Unit, generating gross proceeds of $8,250,000.

“Simultaneously with the consummation of the IPO, the Company consummated the issuance and sale (“ Private Placement ”) of 825,000 Units (the “ Placement Units ”) in a private placement transaction at a price of $10.00 per Placement Unit, generating gross proceeds of $8,250,000.”

REALTY INCOME CORP issued convertible note to qualified institutional buyers for $862.5 million aggregate principal amount.

“announced the closing of its previously announced private offering of $862.5 million aggregate principal amount of 3.500% convertible senior notes due 2029”

VOLITIONRX LTD issued 7,000,350 shares of warrant to Lind Global Asset Management XII LLC for $0.5714 per share.

“a Common Stock Purchase Warrant for the purchase of 7,000,350 shares of our common stock at a price of $0.5714 per share”

VOLITIONRX LTD issued convertible note to Lind Global Asset Management XII LLC for principal amount of $2,400,000.

“we will receive $2,000,000 in funding from Lind in exchange for the issuance to Lind of a Senior Secured Convertible Promissory Note in the principal amount of $2,400,000”

APPYEA, INC issued 245,013,836 shares of common stock to holders of outstanding convertible promissory notes for converted outstanding balance of approximately $0.8 million.

“between December 31, 2025 and January 5, 2026, the holders of outstanding convertible promissory notes of the Company in an aggregate amount of approximately $0.8 million have agreed to convert the outstanding balance of these notes into 245,013,836 shares of the Company’s Common stock (the “Conversion Shares”).”

TRANSUITE.ORG INC. issued Five Million (5,000,000) shares of restricted common stock of common stock.

“the Company will issue Five Million (5,000,000) shares of restricted common stock as consideration for the acquisition described in Items 1.01 and 2.01 above”

Interactive Strength, Inc. issued Class A Incremental Common Warrants to purchase an aggregate of 1,130,713 shares of Common Stock of warrant to accredited investor.

“As previously disclosed, on eight different dates from March 11, 2025 through December 30, 2025, the Investor elected to exercise Class A Incremental Warrants to purchase Class A Incremental Notes for a total principal amount of $11,157,000 and, as a result, was issued Class A Incremental Common Warrants to purchase an aggregate of 1,130,713 shares of Common Stock.”

Interactive Strength, Inc. issued 28,400 shares of Common Stock of common stock to Vertical Investors, LLC for a price per Exchange Share of $5.50.

“On December 31, 2025, the Company and the Lender entered into an Exchange Agreement (the “Exchange Agreement”). Pursuant to the Exchange Agreement, the Company and Lender agreed to reduce the Loan Amount by $156,202 in exchange for the issuance of 28,400 shares of Common Stock (the “Exchange Shares”) to the Lender at a price per Exchange Share of $5.50.”